{"symbol":"LLY","provider":"yahoo-finance","fetchedAt":"2025-12-23T08:23:07.466Z","asOfDate":"2025-12-23","articles":[{"id":"690e6da6-9d98-3549-9fc1-298cfd6447f3","title":"Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”","url":"https://finance.yahoo.com/news/jim-cramer-says-eli-lilly-051614791.html","publisher":"Insider Monkey","publishedAt":"2025-12-23T05:16:14.000Z","relatedTickers":["AMD","AVGO","CVX","MSFT","NVDA","SLG","TSM"],"mainIdea":"Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”","summary":"Insider Monkey: Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything”. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer answered questions about. Inquiring if their portfolio is diversified, a caller highlighted that their top five holdings are LLY, SLG, MSFT, CVX, and TSM. Cramer said: “Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for […] Related tickers mentioned: AMD, AVGO, CVX, MSFT, NVDA, SLG, TSM."},{"id":"8daff7dd-6122-3cb9-ad16-8a3df5fa8764","title":"Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug","url":"https://finance.yahoo.com/m/8daff7dd-6122-3cb9-ad16-8a3df5fa8764/novo-nordisk-jumps-as-fda-oks.html","publisher":"Investor's Business Daily","publishedAt":"2025-12-23T01:09:58.000Z","relatedTickers":["NONOF","NVO","VKTX"],"mainIdea":"Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug","summary":"Investor's Business Daily: Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug. The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight. Related tickers mentioned: NONOF, NVO, VKTX."},{"id":"4c8488a3-403f-3c55-9b54-702e7df9bb01","title":"Pill Version of Wegovy Is Approved for Use in the U.S.","url":"https://finance.yahoo.com/m/4c8488a3-403f-3c55-9b54-702e7df9bb01/pill-version-of-wegovy-is.html","publisher":"The Wall Street Journal","publishedAt":"2025-12-22T23:38:00.000Z","relatedTickers":[],"mainIdea":"Pill Version of Wegovy Is Approved for Use in the U.S.","summary":"The Wall Street Journal: Pill Version of Wegovy Is Approved for Use in the U.S.. Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose."}]}
